Just when it seemed like small-cap orthopedic company NuVasive (NUVA)
had significantly quelled worries about competition (and/or market
share), overall market growth, and its business model, an earnings
warning for the third quarter has thrown it all back into doubt.
Although the magnitude of the company's miss doesn't seem enormous, I
already had my concerns
about the valuation on these shares and it looks like NuVasive is going
to have to sit in the penalty box for at least a little while.
Please read more here:
Back To Square One For NuVasive?
No comments:
Post a Comment